LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has surpassed an important milestone that its technology has been highlighted in more than 100 third-party, peer-reviewed publications in neurology. Driven by increased demand for the company’s Simoa technology, which continues to prove itself as the industry standard for ultra-sensitive biomarker detection, this brings the total number of publications for the company to over 215 across neurology, oncology, cardiology, inflammation and infectious disease.
“This is an incredible moment for Quanterix and further validation of our mission as a research-backed company that puts science first,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix. “It’s also an important time for precision health, as publication results continue to confirm precision medicine as a more effective method for diagnosing and treating diseases. We are honored that many of the world’s leading researchers and academics are increasingly choosing to partner with us for the sensitivity and specificity that only our technology can provide.”
The most recent studies powered by Simoa in this therapeutic category are evidence of breakthroughs that could change the way medical professionals diagnose and treat neurological disorders, and potentially prevent many of them from presenting. Recent impactful studies include:
- The Association of Changes in Plasma Neurofilament Light and Tau Levels with Anesthesia and Surgery Results from the CAPACITY and ARCADIAN Studies: Published in JAMA Neurology, this study shows that general anesthesia and surgery may be associated with neuronal damage in the short term.
- Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants: Published in the Journal of Alzheimer’s Disease, the study found that plasma NfL is inversely associated with cognitive performance in elderly individuals and furthermore, that the onset of axonal injury, reflected by increased plasma NfL, within the preclinical phase of AD may contribute to the pathogenesis of AD.
- Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography: Published in Alzheimer’s & Dementia, this study showed that Plasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.
- Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis: Published in the Multiple Sclerosis Journal, found NfL to be a promising biomarker for the neuro-axonal damage in early multiple sclerosis patients.
- Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression: Published in the Journal of Neurology, Neurosurgery & Psychiatry, this study showed clear promise for tau and NfL as blood-based biomarkers in prion disease.
For more information on Quanterix’ complete list of publications and posters, please visit: https://www.quanterix.com/resources/publications-posters
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
